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Metabolically 35S-labeled calmodulin (CaM) was used
to determine the CaM binding properties of the cardiac
ryanodine receptor (RyR2) and to identify potential
channel domains for CaM binding. In addition, regula-
tion of RyR2 by CaM was assessed in [3H]ryanodine
binding and single-channel measurements. Cardiac sar-
coplasmic reticulum vesicles bound approximately four
CaM molecules per RyR2 tetramer in the absence of
Ca21; in the presence of 100 mM Ca21, the vesicles bound
7.5 CaM molecules per tetramer. Purified RyR2 bound
approximately four [35S]CaM molecules per RyR tet-
ramer, both in the presence and absence of Ca21. At least
four CaM binding domains were identified in [35S]CaM
overlays of fusion proteins spanning the full-length
RyR2. The affinity (but not the stoichiometry) of CaM
binding was altered by redox state as controlled by the
presence of either GSH or GSSG. Inhibition of RyR2
activity by CaM was influenced by Ca21 concentration,
redox state, and other channel modulators. Parallel ex-
periments with the skeletal muscle isoform showed ma-
jor differences in the CaM binding properties and regu-
lation by CaM of the skeletal and cardiac ryanodine
receptors.
The ryanodine receptors (RyRs)1 are large, high conductance
Ca21 release channels found in a specialized subcompartment
of the endoplasmic reticulum of many tissues (1). In muscle
cells, this subcompartment is referred to as the sarcoplasmic
reticulum (SR). There are three known mammalian RyR iso-
forms: RyR1, which is the dominant isoform in skeletal muscle;
RyR2, which is found in cardiac muscle; and RyR3, which is
expressed in many tissues at low levels but is mostly associated
with diaphragm and brain. In both skeletal and cardiac muscle,
Ca21 release through the RyR in response to a signal received
from the T-tubule membrane via the dihydropyridine receptor
is a crucial step in excitation-contraction coupling (2). This
event is highly regulated by small molecules such as Ca21,
Mg21 and adenine nucleotides (3, 4), and through protein-
protein interactions such as with triadin and calmodulin (CaM)
(5–8).
CaM is a small (16.7 kDa) cytosolic protein, the structure of
which has been determined by both x-ray crystallography and
NMR (9, 10). The protein resembles a dumbbell, with two
globular heads linked by a solvent-exposed a-helical stalk.
Each of the N- and C-terminal domains contains two EF-hand
Ca21 binding motifs. Ca21 binding domains I and II in the N
domain have a lower Ca21 affinity (1025 M) and are less Ca21-
selective than the corresponding domains III and IV (1026 M) in
the C domain. CaM binds to and regulates a myriad of target
proteins involved in almost every biological function in three
distinct manners: 1) as CaCaM 2) as apoCaM (without Ca21
bound), and 3) Ca21 independent or constituently bound (11,
12). Each of these binding events occurs through one of several
poorly defined CaM binding motifs, the most common of which
are composed of an amphipathic helix of ;20 amino acid resi-
dues that bind CaCaM or an IQ sequence motif that preferen-
tially binds apoCaM.
CaM shows a biphasic regulation of RyR1, activating the
channel at submicromolar cytosolic Ca21 while inhibiting the
channel at higher Ca21 concentrations (7). RyR2, on the other
hand, does not show activation by apoCaM but is inhibited by
CaCaM in a manner similar to RyR1 (13, 14). Several studies
have reported the stoichiometry of CaM binding to the RyR1.
Early studies using 125I-CaM (7) or fluorescently labeled (15)
CaM indicated a stoichiometry of 1 molecule of CaCaM and
4–6 molecules of apoCaM bound per subunit. Binding site
localization studies with fusion proteins and synthetic peptides
indicated three to six potential binding sites per subunit with a
variable Ca21 dependence (16, 17). More recent studies using
metabolically 35S-labeled CaM indicate a stoichiometry of one
binding site per RyR1 subunit for both apo- and CaCaM (8). A
recent report suggests that cardiac SR vesicles bind five CaCaM
molecules but only 1 apoCaM molecule per RyR2 tetramer (14).
This study presents a systematic analysis of the CaM bind-
ing properties of RyR2 and compares them to RyR1 assayed
under identical conditions. Our data indicate that the purified
RyR2 binds approximately one [35S]CaM molecule per subunit
in both 100 mM Ca21 and 5 mM EGTA. In native cardiac SR
vesicles, [35S]CaM binds approximately two sites per RyR2
subunit in the presence of Ca21 and a single site per subunit in
the absence of Ca21. Two possible explanations for this discrep-
ancy are that a second CaCaM-binding protein in SR vesicles is
lost on purification or that purification induces a conforma-
tional change masking the second site. We have also analyzed
the effects of redox state on CaM binding to both RyR1 and
RyR2. RyR1 and RyR2 are sensitive to redox regulation, show-
ing a 2–3-fold reduction in CaCaM affinity in the presence of
GSSG, which is accentuated in the absence of Ca21 to a 4–9-
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fold reduction in affinity. CaCaM inhibition of native RyR2, un-
like that of RyR1, is greatly diminished by the presence of
two allosteric regulators of the ryanodine receptor, caffeine
and AMPPCP. Unlike RyR1, apoCaM inhibited RyR2, as
determined in [3H]ryanodine binding and single-channel
measurements.
EXPERIMENTAL PROCEDURES
SR Vesicle Preparations and RyR Purification—Heavy SR vesicles
were isolated from rabbit hind limb and back muscle and canine cardiac
muscle as previously described (18). In selected experiments, endoge-
nous CaM was removed by incubating SR vesicles for 30 min at 24 °C
with 1 mM myosin light chain kinase-derived calmodulin binding pep-
tide (CaMBP) in the presence of 100 mM Ca21 followed by centrifugation
through a layer of 15% sucrose to remove complexed CaM and CaMBP.
Where indicated, the centrifugation step was omitted. For purification,
SR vesicles were solubilized in CHAPS, purified by sucrose density
gradient centrifugation, and reconstituted into phosphatidylcholine li-
posomes (19). The endogenous SR-associated concentration of CaM was
determined by the ability of CaM to stimulate phosphodiesterase hy-
drolysis of cAMP as described previously (20).
[35S]Calmodulin Expression and Purification—Calmodulin was met-
abolically labeled with 35S according to a protocol generously provided
by Drs. Gerald Carlson and Kenneth Traxler (University of Missouri at
Kansas City). The cDNA encoding CaM was the generous gift of Dr.
Claude Klee (National Institutes of Health). Escherichia coli trans-
formed with the plasmid DNA were grown in M63 minimal media, and
expression was induced by heat shock at 42 °C followed by the addition
of 1 mCi/100 ml Tran35S-label (ICN Radiochemicals, Costa Mesa, CA).
Expression was allowed to continue for 3 h before the bacteria were
pelleted and resuspended in lysis buffer (50 mM MOPS, pH 7.5, 100 mM
KCl, 1 mM EDTA, 1 mM dithiothreitol, 100 mg/ml lysozyme) and allowed
to lyse overnight at 4 °C. After centrifugation at 30,000 3 g for 30 min,
CaM was purified from the cleared lysate on phenyl-Sepharose in the
presence of 4 mM Ca21 and eluted with 1 mM EDTA. Peak elution
fractions were dialyzed versus two changes of 0.15 M KCl, 20 mM
K1-Pipes, 100 mM CaCl2, pH 7.0. CaM protein concentration was deter-
mined by absorption spectroscopy by the equation [CaM] 5 (A277 2
A320)/e. For expressed CaM, e was assumed to be 0.20 ml/(mg cm) (21).
[35S]Calmodulin Binding—Unless otherwise indicated, SR vesicles
or purified RyR preparations were incubated with 1–300 nM [35S]CaM
in 150 mM KCl, 20 mM K-Pipes, pH 7.0, 0.1 mg/ml bovine serum
albumin (BSA, Sigma A-0281), 0.2 mM Pefabloc, 20 mM leupeptin with
either 5 mM GSH or GSSG and 100 mM (200 mM CaCl2, 100 mM EGTA)
or ,10 nM (5 mM EGTA, no added CaCl2) free Ca
21. Equilibrium
[35S]CaM binding was assayed after incubation at room temperature for
2 h by centrifugation in a Beckman Airfuge for 30 min at 90,000 3 g (SR
vesicles) or for 180 min at 225,000 3 g in a Beckman Type 75 Ti rotor
(soluble and reconstituted, purified RyR preparations). Centrifugation-
based binding assays are ideal in situations of rapid ligand dissociation
and low affinity since the receptor and ligand remain in equilibrium
throughout the separation period. Nonspecific binding, including the
trapped volume of [35S]CaM, was determined using a 100–1000-fold
excess of unlabeled calmodulin (SR vesicles) or by determining
[35S]CaM binding to CHAPS-solubilized phospholipid or liposomes that
lacked RyR2. Bound [35S]CaM was determined by scintillation counting
after solubilization of pellets in Tris-HCl buffer, pH 8.5, containing 2%
sodium dodecylsulfate. The time course of [35S]CaM dissociation was
determined at 23 °C with the use of a filter assay. To minimize nonspe-
cific binding of [35S]CaM, Whatman GF/B filters were blocked for 1 h in
0.15 M KCl, 10 mM K-Pipes, pH 7.0, buffer containing 10 mg/ml BSA.
Vesicles on the filters were washed with 3 3 5 ml of 0.15 KCl, 10 mM
K-Pipes, pH 7.0, buffer containing 0.1 mg/ml BSA.
[3H]Ryanodine Binding—Specific [3H]ryanodine binding was deter-
mined in the buffer system used for [35S]CaM binding after incubation
with 1–2 nM [3H]ryanodine for 20 h at 23 °C as previously described
(18). Bmax values of [
3H]ryanodine binding were determined by Scat-
chard analysis or with 50 nM [3H]ryanodine in 0.6 M KCl buffer.
Fusion Protein Generation and Expression—Fusion proteins span-
ning the full-length coding sequences of rabbit RyR1 (fused to TrpE or
glutathione S-transferase) and RyR2 (fused to glutathione S-transfer-
ase) were generated by using polymerase chain reaction to add unique
restriction sites to the 59 and 39 ends of the region of interest (RyR2) or
using existing restriction sites (RyR1) followed by cloning in-frame into
pATH or pGEX-5X (RyR1) or pGEX-5X (Amersham Pharmacia Biotech,
RyR2). The sequences expressed for each fusion protein are as follows:
for RyR2, FP1 (1–333), FP2 (263–615), FP3 (561–908), FP4 (872–1207),
FP5 (1157–1509), FP6 (1487–1817), FP7 (1791–2112), FP8 (2084–
2401), FP9 (2385–2754), FP10 (2724–3016), FP11 (3003–3182), FP12
(3160–3352), FP13 (3298–3595), FP13short (3298–3577), FP14 (3543–
3961), FP15 (3931–4229), FP16 (4205–4478), FP17 (4404–4563), FP18
(4548–4748), FP19 (4726–4968); for RyR1, FPA (1–282), FPB (282–
FIG. 1. Analysis of 35S-calmodulin binding to cardiac SR vesi-
cles and purified RyR2. Cardiac SR vesicles (A) and proteoliposomes
containing the purified RyR2 (B) were incubated with increasing con-
centrations of [35S]CaM in the presence of either 100 mM free Ca21
(filled symbols) or 5 mM EGTA (open symbols) and reduced (GSH,
circles) or oxidized (GSSG, triangles) glutathione. Averaged [35S]CaM/
[3H]ryanodine binding ratios and KD values from a total of between 5
and 16 experiments are shown in Table I. C, Bmax (left axis, filled circles)
and KD (right axis, open circles) values for [
35S]CaM binding were
determined as a function of free Ca21 concentration. The data are
mean 6 S.D. for 8 experiments at ,10 nM Ca21, 3 experiments at all
other [Ca21].
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799), FPC (799–1209), FPD (1209–1632), FPE (1632–2157), FPF
(2156–2592), FPG (2502–2874), FPH (2804–3224), FPI (3225–3662),
FPJ (3622–3880), FPK (3879–4222), FPL (4223–4302), FPM (4302–
4430), FPN (4431–4771), FPO (4771–5037). Fusion proteins were ex-
pressed in the BL21 Gold strain of E. coli (Stratagene) by induction
(with 1 mM isopropyl-1-thio-b-D-galactopyranoside for GST and 10
mg/ml indoacrylic acid for TrpE fusion proteins) and a 2-h incubation at
37 °C. Whole cell pellets were collected by centrifugation at 1500 3 g for
15 min followed by resuspension in phosphate-buffered saline contain-
ing Complete protease inhibitors (Roche Molecular Biochemicals) and
lysis by sonication.
[35S]Calmodulin Overlays—Equivalent amounts of each fusion pro-
tein (as judged by Coomassie Brilliant Blue stain and Western analysis)
were loaded onto 10% SDS-polyacrylamide electrophoresis gels. After
electrophoresis, the proteins were transferred to nitrocellulose
(0.45-mm pore, Schleicher & Schuell) by semidry techniques. The mem-
branes were blocked (2 3 30 min) in 150 mM KCl, 20 mM K-Pipes, pH
7.0, 1 mg/ml BSA with either 100 mM CaCl2 or 5 mM EGTA. The
membranes were then exposed to 100 nM [35S]CaM in 150 mM KCl, 20
mM K-Pipes, pH 7.0, 0.04% Tween 20 with the appropriate Ca21 con-
centration for 1 h at room temperature followed by four 10-min washes in
blocking buffer at 4 °C. The membranes were dried overnight then ex-
posed to Biomax MR x-ray film (Eastman Kodak Co.) for 1–10 days.
Single-channel Analysis—Single-channel measurements using puri-
fied RyR2 were carried out as previously described (18) in planar lipid
bilayers containing phosphatidylethanolamine, phosphatidylserine,
and phosphatidylcholine in the ratio of 5:3:2 (25 mg of total phospho-
lipid/ml of n-decane). The side of the bilayer to which the proteolipo-
somes containing the purified RyR2 were added was defined as the cis
(cytoplasmic) side. The trans (SR lumenal) side of the bilayer was
defined as ground. Measurements were made with symmetrical 0.25 M
KCl, 20 mM K-Pipes, pH 7.0, with 50 mM free Ca21 in the trans (lume-
nal) chamber. The cis (cytosolic) solution was varied according to ex-
perimental conditions. Data were acquired using test potentials of 635
mV and were sampled at 10 kHz and filtered at 2 kHz. Channel open
probabilities (Po) were determined from at least 2 min of recordings for
each condition.
Data Analysis—Free Ca21 concentrations were determined as previ-
ously described (18). All data analyses were done using SigmaPlot
version 5.
RESULTS
[35S]Calmodulin Binding to RyR1 and RyR2—Fig. 1A shows
the results of Scatchard analysis of CaM binding to cardiac SR
vesicles in reducing (5 mM reduced glutathione, GSH, circles)
and oxidizing (5 mM oxidized glutathione, GSSG, triangles)
conditions with 100 mM (filled symbols) and ,10 nM free (open
symbols) Ca21, respectively. The data are also summarized in
Table I. In the presence of 100 mM Ca21, cardiac SR vesicles
bound 7.5 mol of [35S]CaM/mol of bound [3H]ryanodine. Since
there is only one high affinity [3H]ryanodine binding site per
tetramer (3, 4), this suggests that in the presence of Ca21,
RyR2 binds 2 CaM molecules per subunit or that other CaM-
binding proteins are present in cardiac SR vesicles. One of the
FIG. 2. Dissociation of bound 35S-
calmodulin. Cardiac SR vesicles were
prebound with 100 or 200 nM [35S]CaM in
100 mM free Ca21 (filled symbols) or 5 mM
EGTA (open symbols), respectively, in the
presence of 5 mM GSH (circles) or 5 mM
GSSG (triangles) and then were diluted
60-fold into media containing 50 nM non-
radioactive CaM and either 100 mM free
Ca21 (filled symbols) or 5 mM EGTA (open
symbols). The averaged time constants (in
min) of [35S]CaM dissociation 6S.D. of
3–5 experiments for RyR2 and RyR1, re-
spectively, was 8.5 6 2.9 and 12.4 6 4.2
(Ca21 1 GSH), 9.0 6 2.6 and 8.9 6 3.4
(Ca21 1 GSSG), 0.7 6 0.5 and 3.8 6 1.0
(EGTA 1 GSH), and 0.7 6 0.5 and 4.0 6
0.9 (EGTA 1 GSSG).
TABLE I
[35S]Calmodulin binding to cardiac and skeletal SR vesicles and purified RyR2 and RyR1
Values are the mean 6 S.D. with the number of experiments in parenthesis. [35S]CaM/[3H]ryanodine is the ratio of Bmax values in pmol/mg for
[35S]CaM and [3H]ryanodine as determined by either Scatchard analysis or using saturating concentrations.





1GSH 7.4 6 1.5 (12) 3.5 6 2.0 (12) 3.8 6 0.8 (5) 72 6 30 (5)
1GSSG 7.6 6 1.3 (5) 6.8 6 2.3 (5)a 2.6 6 0.8 (5) 261 6 103 (5)a
Purified RyR2
1GSH 3.9 6 1.0 (5) 5.0 6 2.2 (5) 3.8 6 1.5 (6) 54 6 34 (6)
Skeletal SR
1GSH 4.9 6 0.7 (16) 4.7 6 1.6 (16) 4.2 6 0.8 (8) 12.9 6 3.4 (8)
1GSSG 5.3 6 0.9 (5) 12.1 6 1.8 (5)a 4.4 6 0.7 (5) 108 6 41 (5)a
Purified RyR1
1GSH 4.6 6 0.9 (6) 5.5 6 2.6 (6) 3.3 6 1.3 (6) 5.4 6 2.5 (6)
a P , 0.01 when compared to KD in presence of GSH by unpaired Student’s t test.
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binding sites appeared to be CaCaM-specific since, in the ab-
sence of free Ca21, the stoichiometry approximates one CaM
molecule per RyR2 subunit. Skeletal SR vesicles bound ;1
molecule of [35S]CaM per RyR1 subunit both in the presence
and absence of Ca21, as has been previously reported (8). The
results from these experiments have been corrected for the
presence of endogenous CaM in the vesicle preparations (1.0 6
0.6 (n 5 4) and 0.13 6 0.05 (n 5 5) CaM per subunit for cardiac
and skeletal SR vesicles, respectively), as determined by phos-
phodiesterase activation assay.
After purification of RyR2 from cardiac SR vesicles (shown in
Fig. 1B) in the presence of 5 mM GSH and after reconstitution
into proteoliposomes, the CaCaM:[3H]ryanodine binding stoi-
chiometry dropped from ;2 to 1 molecule per subunit in the
presence of 100 mM Ca21, suggesting that other CaM-binding
proteins have been removed. Alternatively, one of the two Ca-
CaM binding sites in RyR2 may have been conformationally
destroyed or buried during purification. We also considered the
possibility that endogenous CaM remains associated with the
purified RyR. However, if there is such a population of CaM, it
would have to be very tightly bound to the receptor and, there-
fore, without effect on CaCaM binding measured in this study,
which has a high rate of dissociation (see Fig. 2). Purification
did not significantly alter the CaM:[3H]ryanodine binding stoi-
chiometry for RyR2 in the absence of Ca21 or for RyR1 both in
the presence and absence of Ca21 (Table I).
Decrease in free Ca21 concentration from 100 mM to ,10 nM
lowered the affinity for CaM in cardiac SR vesicles 20-fold in
the presence of reduced glutathione (GSH) (Fig. 1, A and B,
circles) and ;40-fold in the presence of oxidized glutathione
(GSSG) (triangles). In either the presence or absence of Ca21,
oxidized glutathione decreased the affinity for CaM relative to
reduced glutathione without changing Bmax. Likewise, the
CaM binding affinity of RyR1 was reduced 2.5-fold by GSSG in
the presence of Ca21 and 9-fold in the absence, again without
changes in Bmax (Table I).
The Ca21-dependent changes in CaM binding to cardiac SR
vesicles are shown in Fig. 1C. Increase in free Ca21 from ,10
to 100 nM was without significant effect on CaM binding affin-
ity or CaM:[3H]ryanodine binding stoichiometry, implying that
there is apoCaM binding at resting cytosolic Ca21 levels. The
binding stoichiometry nearly doubled as Ca21 concentration
was raised to 600 nM, to a value close to the one at 100 mM Ca21.
Conversely, the increase in CaM binding affinity occurred over
a broad Ca21 concentration range, requiring Ca21 concentra-
tions between 1 and 10 mM for maximal affinity.
Dissociation experiments were performed to determine the
effects of redox state on the stability of the apoCaM and CaCaM
RyR complexes. As shown in Fig. 2, the rate of dissociation from
RyR2 is largely independent of whether CaM is bound in the
presence of 5 mM GSH or 5 mM GSSG. The rate of dissociation
in EGTA containing media occurred with a t1/2 of ;40 s. The
rate of dissociation was decreased by more than 10-fold in the
presence of Ca21, occurring with t1/2 of ;9 min. The results
suggest that the rate of dissociation of CaM from RyR2 is
largely independent of redox state but rather on whether Ca21
is present in the dissociation buffer, with apoCaM dissociating
at a significantly greater rate than CaCaM. Similar results
were obtained for RyR1 (see the legend of Fig. 2), with less
pronounced differences between the rates of dissociation of
CaCaM and apoCaM.
Identification of Potential Calmodulin Binding Sites—To
identify potential calmodulin binding sites within the linear
sequence of RyR1 and RyR2, we have generated fusion proteins
spanning the full coding sequence of the subunit. The design for
the fusion proteins is indicated under “Experimental Proce-
dures.” RyR1 sequences were fused to TrpE (with the exception
of RyR1 FP E, L, M, and N, which are fused to GST to improve
FIG. 3. Identification of potential
calmodulin binding sites. Fusion pro-
teins 1–19 derived from the full-length
RyR2 sequence (fused to GST) as well as
GST without an insert were expressed in
E. coli and equivalent amounts of ex-
pressed fusion protein as well as non-
transformed (NT) E. coli, as judged by
Coomassie-stained SDS-polyacrylamide
electrophoresis gels, were transferred to
nitrocellulose. After blocking with 1
mg/ml BSA, 100 nM [35S]CaM was over-
laid for 1 h in 0.15 M KCl, 20 mM K-Pipes,
pH 7, 0.04% Tween 20 with 100 mM CaCl2
(A) or 5 mM EGTA (B). After four washes
in blocking buffer and overnight drying,
the membranes were exposed to x-ray
film.
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expression), whereas the RyR2 fusion proteins were fused to
GST. Since the vast majority of the fusion proteins were insol-
uble, [35S]CaM overlays were performed with whole cell frac-
tions. Fig. 3A shows that, in the presence of 100 mM CaCl2 and
100 nM [35S]CaM, five of the RyR2 fusion proteins showed
pronounced [35S]CaM binding. CaM binding was detected for
RyR2 fusion proteins 2 (aa 263–615), 10 (2724–3016), 13
(3298–3595), 14 (3543–3961), and 18 (4548–4748), whereas
inconsistent binding was observed for fusion proteins 1 (1–333),
3 (561–908), 6 (1487–1817), and 16 (4205–4478). Fig. 3B shows
that in 5 mM EGTA, the binding to FP10 is only slightly
decreased, whereas the binding to the remaining fusion pro-
teins is greatly reduced, indicative of a Ca21 dependence of
binding to FPs 2, 13, 14, and 18.
The CaM binding to FP13 is localized to the C-terminal
portion of the fusion protein since a truncated form, FP13short
(3298–3577), does not bind either CaCaM or apoCaM in over-
lay experiments (not shown). Hence, it is likely that FPs 13 and
14 contain the same CaM binding domain. RyR1 fusion pro-
teins I (aa 3225–3662) and M (4302–4430) bound CaCaM; in
the presence of 5 mM EGTA, binding to FPM was not signifi-
cantly altered, and binding to FPI was abolished (not shown).
These results suggest that there are multiple potential CaM
binding sites within the linear RyR sequences, particularly
RyR2. Most appear to be buried in the large intact RyR2 chan-
nel protein because their number exceeds the number of CaM
binding sites in the intact receptor (Table I).
Functional Implications of Calmodulin Binding—It has been
previously reported that CaCaM inhibits Ca21 efflux from both
skeletal and cardiac SR vesicles (13, 22). In addition, CaCaM
inhibits [3H]ryanodine binding to RyR1 in skeletal SR vesicles
(7, 14, 23) with little effect on [3H]ryanodine binding to RyR2 in
cardiac SR vesicles (14). We have used a CaM binding peptide
derived from the myosin light chain kinase (CaMBP) to deter-
mine and correct for the presence of endogenous calmodulin
(see above) in studies of [3H]ryanodine binding, which has not
been done in previous studies. Relatively low CaMBP concen-
trations (0.1 mM) were sufficient to reduce [35S]CaM binding in
the presence of 100 mM free Ca21 to skeletal SR vesicles to 4%
of the control value (Fig. 4A). For cardiac SR vesicles, a higher
CaMBP concentration (1 mM) was required to reduce [35S]CaM
binding to comparable, low levels. It is crucial that relatively
low concentrations of CaMBP be used if the experiments are
done in the presence of the peptide since, as shown in Fig. 4B,
vesicles assayed in the presence of high concentrations of
CaMBP show a marked stimulation of [3H]ryanodine binding
to skeletal SR in either GSH or GSSG by CaMBP at concen-
trations greater than 1 mM. A lower degree of stimulation was
observed with cardiac SR. CaMBP was less effective in reduc-
ing [35S]CaM binding to SR vesicles at [Ca21] , 1 mM. Where
indicated, experiments were therefore done with SR vesicles
pretreated with CaMBP, as described under “Experimental
Procedures.”
To correlate the binding of CaCaM to the inhibition of [3H]ry-
anodine binding, we measured [3H]ryanodine binding at in-
creasing concentrations of CaM both in the presence of GSH
and GSSG for cardiac (Fig. 5) and skeletal (not shown) SR
vesicles. For cardiac SR, a higher extent of inhibition was
observed in GSH than GSSG. The KHi for inhibition of ryano-
dine binding (0.6 6 0.2 and 1.7 6 0.7 nM for RyR2 in GSH and
GSSG, respectively) was considerably lower than the KD for
[35S]CaM binding (see Table I). The Hill coefficients for CaM
inhibition of ryanodine binding to RyR2 were 1.0 6 0.3 both in
GSH and GSSG. Skeletal SR also had KHi values (legend of Fig.
5) that were lower than the KD values and had Hill coefficients
near unity. The results suggest that inhibition of ryanodine
binding perhaps requires only a single CaCaM bound/tetramer.
CaM inhibition of [3H]ryanodine binding is also modulated
by various regulators of the RyRs as indicated in Fig. 6 and
Table II. At [Ca21] . 1 mM, CaM (1 mM) inhibition of both
cardiac and skeletal RyR is observed in both oxidizing and
reducing conditions in the absence of MgAMPPCP (AMPPCP is
a nonhydrolyzable ATP analogue). CaM inhibits [3H]ryanodine
binding to RyR2 by both rendering the receptor less sensitive to
activation by Ca21 and more sensitive to inhibition at high Ca21
as well as by lowering the maximal level of [3H]ryanodine bind-
ing (Fig. 6, upper left panel). In the presence of MgAMPPCP
and at [Ca21] , 10 mM, CaM inhibits cardiac SR ryanodine
binding in both reducing and oxidizing conditions (Fig. 6, upper
right panel). However, at [Ca21] . 10 mM, CaM inhibits RyR2
ryanodine binding only in reducing conditions. The lower left
panel of Fig. 6 indicates that in agreement with a previous
report (24), skeletal SR [3H]ryanodine binding is markedly
FIG. 4. CaMBP effects on [35S]calmodulin and [3H]ryanodine
binding. A, [35S]CaM binding in 10 nM [35S]CaM and 100 mM free Ca21
was determined in either 5 mM GSH (circles) or GSSG (triangles) as a
function of increasing CaMBP concentration to SR vesicles from either
cardiac (filled symbols) or skeletal (open symbols) muscle. B, cardiac or
skeletal SR vesicles were preincubated with 1 mM CaMBP and centri-
fuged to remove endogenous CaM and added CaMBP, then [3H]ryano-
dine binding was determined in 0.15 M KCl, 20 mM K-Pipes, pH 7.0, 100
mM Ca21, 0.1 mg/ml BSA in either 5 mM GSH or GSSG with increasing
concentrations of CaMBP. Data are the mean 6 S.D. of 3–4
experiments.
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inhibited in the presence of GSH. [3H]Ryanodine binding to
skeletal SR is activated by CaM at low Ca21 concentrations
both in the absence or presence of MgAMPPCP and the pres-
ence of GSH (see Table II) or GSSG and inhibited at higher
Ca21 concentrations in both oxidizing and reducing conditions
(Fig. 6, lower two panels). In the presence of 5 mM MgAMPPCP,
free Ca21 concentrations in excess of 0.3 mM were not tested
because of difficulties in keeping Ca21 in solution.
In Table II, the effects of CaM on [3H]ryanodine binding to
RyR2 and RyR1 are compared in 0.1 and 100 mM Ca21 media
that contained 10 mM caffeine, 5 mM AMPPCP, or 1 mM Mg21.
ApoCaM significantly inhibits RyR2 in reducing conditions in
FIG. 5. Calmodulin inhibition of
[3H]ryanodine binding to cardiac SR
vesicles. Cardiac SR vesicles were prein-
cubated with 1 mM CaMBP and centri-
fuged to remove endogenous CaM and
added CaMBP. [3H]Ryanodine binding
was determined in 0.15 M KCl, 20 mM
K-Pipes, pH 7.0, 100 mM Ca21, 0.1 mg/ml
BSA, 0–2500 nM CaM, and either 5 mM
GSH (circles) or GSSG (triangles). Free
CaM concentrations were measured on
paired samples using [35S]CaM. Solid
lines were obtained according to the equa-
tion B 5 Bo (1 1 (([CaM]/KHi)
n
Hi)21, where
B and Bo are bound [
3H]ryanodine in the
presence and absence of CaM. The aver-
aged Hill inhibition constants (KHi) 6
S.D. of 3–4 experiments in the presence of
GSH and GSSG were 0.6 6 0.2 nM and
1.7 6 0.7 nM, respectively. Corresponding
Hill coefficients (nHi) were 1.0 6 0.3 and
1.0 6 0.3. Corresponding KHi for RyR1
were 1.6 6 0.2 nM and 4.7 6 0.4 nM, and
nHi were 1.2 6 0.4 and 1.1 6 0.3.
FIG. 6. Ca21 dependence of calmod-
ulin inhibition of [3H]ryanodine
binding. [3H]Ryanodine binding was de-
termined as a function of free Ca21 con-
centration for both cardiac (RyR2) and
skeletal (RyR1) SR vesicles either in the
absence (2MgA) or presence (1MgA) of 5
mM MgAMPPCP and either in the ab-
sence (circles) or presence (triangles) of 1
mM added CaM and either with 5 mM GSH
(open symbols) or 5 mM GSSG (filled sym-
bols). Endogenous CaM was removed by
pretreating vesicles with 1 mM CaMBP
(experiments at ,1 mM Ca21) followed by
centrifugation or dissociated from the re-
ceptor by carrying out the binding assay
in the presence of 0.5 mM CaMBP (exper-
iments at . 1 mM Ca21). The averaged
data 6 S.D. of 3–4 experiments are fit to
a two-site (one activation, one inhibition)
logistic function (34).
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either the presence or absence of AMPPCP. This apoCaM in-
hibition was attenuated in the presence of caffeine or in oxidiz-
ing conditions. CaCaM inhibition of RyR2 was significant in
control (1GSH) and in the presence of 1 mM MgCl2, with no
significant effects in the presence of caffeine or AMPPCP.
ApoCaM stimulation of RyR1 under both oxidizing and reduc-
ing conditions was maintained in the presence of 10 mM caf-
feine or 5 mM AMPPCP, compounds that further sensitize the
RyR1 ion channel to low concentrations of Ca21. CaCaM inhi-
bition of ryanodine binding to RyR1 was observed under each
condition, although the magnitude of the inhibition was de-
creased in the presence of AMPPCP. The inhibition by CaCaM
in AMPPCP was lower in the presence of GSSG than GSH,
whereas the inhibition in the presence of caffeine was unaf-
fected by the redox state of glutathione.
Calmodulin Interaction with Purified Ryanodine Receptors—
Purification of RyR1 by CHAPS solubilization and reconstitu-
tion into proteoliposomes had little effect on the equilibrium
[35S]CaM binding properties, as indicated in Table I; further-
more, CaCaM inhibition of [3H]ryanodine binding to purified
RyR1 was comparable with that of SR vesicles (not shown).
Purification of RyR2, however, decreased the stoichiometry of
CaCaM binding without affecting the KD. In addition, purified
RyR2 (either solubilized or reconstituted) failed to show any
inhibition of [3H]ryanodine binding by CaCaM in equilibrium
binding experiments.
Single-channel measurements using purified RyR2 indicate
that in an applied electrical field CaM inhibition of RyR2 is
maintained after purification and reconstitution into proteoli-
posomes (Fig. 7, Table III). In Fig. 7A, a single channel was
recorded in the presence of 100 mM cis (cytoplasmic) Ca21. The
addition of 1 mM cis CaM reduced channel open probability (Po)
from 0.62 to 0.27. The Hill inhibition constant and coefficient of
7 experiments were 42 6 1 nM and 1.4 6 0.1, respectively (Fig.
7B). In 100 mM free cis Ca21 and symmetrical 0.25 M KCl, the
addition of 1 mM CaM to the cis chamber reduced Po from 0.73 6
0.09 to 0.32 6 0.08 (n 5 7) (Table III). The inhibition of purified
RyR2 was attributed to a decrease in mean open time from
9.83 6 6.57 to 1.45 6 0.47 ms (n 5 5) (statistically significant
normalized decrease in open time of 44 6 12%) without other
significant effects on channel gating parameters. The inhibi-
tory effect was magnified in the presence of 2 mM Mg21 and 100
mM free Ca21 with a decrease in Po from 0.51 6 0.15 to 0.05 6
0.03 (n 5 4). As in the [3H]ryanodine binding studies using SR
membranes, MgATP reversed the inhibition by CaM at 100 mM
free Ca21. At 100–200 nM free Ca21 concentrations, the addi-
tion of 1 mM CaM had a weak inhibitory effect alone as well as
in the presence of caffeine; this inhibition was statistically
significant only when the data were normalized (Po(1CaM)/
Po(2CaM) 5 0.22 6 0.05 for control and 0.66 6 0.10 in the
presence of caffeine). Thus, RyR2 was not activated by
apoCaM, as is the case for RyR1 (7). It therefore appears that
purification of RyR2 alters the conformation of the channel
sufficiently to mask in [3H]ryanodine binding measurements
the CaCaM binding site that is responsible for inhibition of the
channel, but that this site, mediating inhibition by CaCaM and
presumably apoCaM (Fig. 1C), can be recovered in single-
channel measurements by the application of an electrical field.
DISCUSSION
It has been known for more than 10 years that the Ca21-
binding protein calmodulin is capable of inhibiting Ca21 re-
lease from isolated SR membranes both from cardiac and skel-
etal muscle (13, 22). Since that time, extensive work has
attempted to characterize the nature of CaM binding to the
ryanodine receptor. Initial studies using either 125I (7) or fluo-
rescently (15) labeled CaM found that there are as many as six
binding sites for apoCaM on each of the four RyR1 subunits
that compose the functional channel. This number was sup-
ported in part by studies using fragments of the full-length
subunit, which indicated that there were three regions that
strongly bound CaM as well as at least three other regions that
had weaker CaM binding (16, 17). With the exception of one
site, CaM binding was Ca21-dependent, which indicated differ-
ences in the Ca21 dependence of CaM binding to the intact
receptor and isolated fragments. More recent studies using SR
membranes and 35S metabolically labeled CaM indicate that
the tetrameric skeletal muscle channel complex binds a total of
four CaM molecules both for apo- and CaCaM or an average of
one CaM per subunit (8). The implication of these studies is
that chemical modification induces changes in calmodulin lead-
ing to nonphysiological binding. The data that we have pre-
sented here show that, in agreement with previous studies
using [35S]CaM, the skeletal muscle isoform binds ;4 mole-
cules of CaM per tetramer both in the presence and absence of
Ca21. Furthermore, the stoichiometry of CaM binding to RyR1
TABLE II
Regulation of native RyR1 and RyR2 by calmodulin in the presence of other ligands
Bound [3H]ryanodine (pmol/mg) was determined under the indicated conditions with vesicles pretreated with CaMBP (2CaM) to complex




2CaM 1CaM 2CaM 1CaM
pmol/mg of protein
In 5 mM GSH
0.1 mM Ca21 0.013 6 0.003 0.005 6 0.002a 0.002 6 0.002 0.012 6 0.002a
110 mM caffeine 0.59 6 0.04 0.50 6 0.07 0.08 6 0.01 0.14 6 0.02a
15 mM AMPPCP 0.06 6 0.02 0.025 6 0.005a 0.025 6 0.005 0.09 6 0.03a
100 mM Ca21 1.2 6 0.1 0.8 6 0.1a 0.17 6 0.01 0.04 6 0.01a
110 mM caffeine 1.2 6 0.1 1.2 6 0.2 0.19 6 0.01 0.04 6 0.01a
15 mM AMPPCP 1.4 6 0.1 1.3 6 0.1 3.3 6 0.3 2.1 6 0.2a
11 mM Mg21 0.90 6 0.05 0.30 6 0.04a 0.03 6 0.01 0.01 6 0.01
In 5 mM GSSG
0.1 mM Ca21 0.025 6 0.006 0.017 6 0.003 0.01 6 0.01 0.06 6 0.01a
110 mM caffeine 0.58 6 0.05 0.55 6 0.05 0.4 6 0.1 0.7 6 0.1a
15 mM AMPPCP 0.17 6 0.02 0.11 6 0.04 0.30 6 0.05 0.85 6 0.20a
100 mM Ca21 1.3 6 0.1 1.1 6 0.1 1.2 6 0.1 0.2 6 0.1a
110 mM caffeine 1.3 6 0.1 1.1 6 0.1 1.3 6 0.1 0.2 6 0.1a
15 mM AMPPCP 1.4 6 0.1 1.4 6 0.1 3.8 6 0.3 3.5 6 0.3
11 mM Mg21 1.2 6 0.1 0.8 6 0.1a 0.20 6 0.05 0.03 6 0.01a
a P , 0.05 when compared to bound [3H]ryanodine in the absence of CaM by Student’s unpaired t test.
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is not influenced by the redox state, whereas previous studies
using sulfhydryl-reacting agents and [125I]CaM binding have
indicated a decrease in the number of apoCaM binding sites (23).
Very little is known about the CaM binding properties of the
cardiac isoform of the ryanodine receptor. A recent report by
Fruen et al. (14) suggests that cardiac SR membranes bind a
single molecule of CaCaM per subunit. Their results also indi-
cate that the binding of apoCaM is greatly reduced, with a
stoichiometry of ;1 molecule per tetramer. The most likely
cause of the discrepancy between their report and ours (7.5
molecules of CaCaM per tetramer and 4 molecules apoCaM per
tetramer) is due to their use of a filtration-based assay given
the rapid rate of dissociation of CaM from the cardiac receptor,
particularly in the presence of EGTA, where the t1/2 for disso-
ciation was about 40 s. For both skeletal and cardiac SR vesi-
cles, the CaM binding affinity was decreased both by the re-
moval of Ca21 and by the presence of oxidizing GSSG. This
agrees with previous reports suggesting that superoxide anion
decreases cardiac SR CaM content (25) and sulfhydryl-reacting
reagents diminish CaM binding and inhibition of RyR1 (23, 26).
The Ca21-dependent change in stoichiometry appears to be the
result of Ca21 binding to CaM given the highly cooperative
nature of the increase, whereas the increase in affinity may be
due to Ca21 binding to the cardiac ryanodine receptor, as
previously suggested for the skeletal receptor (27).
Recent data suggest there is a single CaM binding domain
that binds both apo- and CaCaM at distinct but closely apposed
sequences (8, 29). Attempts to localize the CaM binding domain
in RyR2 illustrated additional differences between skeletal and
cardiac ryanodine receptors. Only two potential CaM binding
sites were identified in fusion proteins derived from RyR1; one
of which, fusion protein I (aa 3225–3662), bound only CaCaM,
whereas the other, fusion protein M (aa 4302–4430), bound
CaM both in 100 mM Ca21 as well as 5 mM EGTA. The fusion
proteins derived from the RyR2 sequence, however, revealed
many more potential CaM binding sites. Two overlapping sites
(FP13, aa 3298–3595, and FP14, aa 3543–3961) displayed pro-
nounced CaM binding. Fusion proteins I (RyR1) and 13 and 14
(RyR2) contain a sequence implicated in each study, localizing
CaM binding sites in the RyR1 sequence (8, 16, 17, 28). C-
terminal truncation of 18 amino acids from FP13 (FP13Short,
aa 3298–3577) removed both Ca21- and apoCaM binding in
overlay experiments, suggesting that the sequence (RyR2 aa
3578–3595) HPQRSKKAVWHKLLSKQR is crucial for confer-
ring CaM binding. Furthermore, our data imply that the affin-
ity of CaM binding to this site is Ca21-dependent. A portion of
this sequence with additional C-terminal residues (fusion pro-
tein PC26 RyR1, aa 3552–3661, and peptide PM2 RyR1, aa
3617–3634 and RyR2 aa 3583–3601) was found to bind calmod-
ulin in 10 mM Ca21 but not in 10 mM EGTA (17); the corre-
sponding peptide derived from RyR2 was also found to have
similar Ca21 dependence (28). Interestingly, this single domain
has been implicated in both CaCaM and apoCaM binding, as
both forms are capable of protecting RyR1 from trypsin cleav-
age at arginines 3630 and 3637 (8). A recent publication has
used peptides derived from this RyR1 CaM binding domain to
further refine the putative apo and CaCaM binding sites as an
N-terminal CaCaM-specific domain from 3614 to 3634 and an
overlapping domain also capable of binding apoCaM from 3625
to 3644 (29). In RyR2, however, the results do not entirely
agree, as FP13 bound both apo- and CaCaM (albeit to different
extents) but does not contain this apoCaM domain. Further-
more, in the Rodney et al. (29) study, a peptide (3614-
KSKKAVWHKLLSKQ-3627), which agrees with the critical
sequence for CaM binding to RyR2 FP13, was unable to bind
either Ca21 or apoCaM. The results from our localization of
potential CaM binding sites as well as those reported by others
are summarized in Fig. 8.
Previous reports show that the activity of the skeletal muscle
ryanodine receptor is stimulated by CaM at low free Ca21
concentrations (7, 14). This effect appears to be lacking in the
few studies performed to date using cardiac SR vesicles (14).
Recently it was also shown that cardiac SR vesicle ryanodine
binding was not inhibited by CaCaM in the presence of adenine
nucleotides, although SR Ca21 efflux was inhibited by CaM in
FIG. 7. Effect of cytosolic calmodulin on single purified RyR2
ion channels. Proteoliposomes containing purified RyR2 were fused
with lipid bilayers. A, single-channel currents were recorded at 35 mV
(upward deflection from closed levels, c-) in symmetric 0.25 M KCl, 20
mM K1-Pipes, pH 7.0, media containing 5.08 mM CaCl2 and 5 mM EGTA
(free Ca21 of 100 mM). Top trace, control, Po 5 0.62. Bottom trace, after
the addition of 1 mM CaM, Po 5 0.27. B, dependence of cardiac Ca
21
release channel activity on CaM concentration. Relative channel open
probability (Po/Po,control) was obtained from 7 single-channel recordings
similar to those shown in A. Solid lines were obtained according to the
equation Po 5 Po,control(1 1 (([CaM]/KHi)
n
Hi)21 where Po and Po,control are
single-channel activities in the presence and absence of CaM. The Hill
inhibition constant and coefficient 6 S.D. of seven experiments were
42 6 1 nM and 1.4 6 0.1, respectively. * and ** indicate the means of
data were significantly different from control at p , 0.05 and p , 0.001,
respectively.
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a manner similar to previous Ca21 efflux measurements (14).
We show here that inhibition of RyR2 by CaM is dependent on
the assay conditions. [3H]Ryanodine binding to cardiac SR
vesicles was inhibited by CaCaM in the absence and presence
of Mg21 and adenine nucleotide, with the effect being more
pronounced at [Ca21] , 10 mM in the presence of GSH. CaCaM
was without a significant effect at 100 mM Ca21 in the presence
of GSSG and adenine nucleotide or caffeine. ApoCaM inhibited
[3H]ryanodine binding to cardiac SR in the absence and pres-
ence of AMPPCP. In single-channel measurements, apoCaM
had a small inhibitory effect in the absence and presence of
caffeine.
We have also found that, although the use of the CaMBP is
necessary to eliminate the effects of endogenous SR calmodu-
lin, which is associated with both the skeletal and cardiac SR
vesicles, it is imperative that it be used at low concentrations
since it had a pronounced stimulatory effect on skeletal [3H]ry-
anodine binding after preincubation of the vesicles to remove
the endogenous CaM. Since CaMBP is derived from a CaCaM-
specific binding protein, it is ineffective at removing endoge-
nous CaM in the absence of Ca21. To correct for the effect of
endogenous apoCaM, we first removed endogenous CaM by
incubation with CaMBP in the presence of Ca21 followed by
centrifugation.
Purification of RyR2 decreases the stoichiometry of CaCaM
binding, eliminating one site for [35S]CaCaM per subunit with-
out affecting apoCaM binding, an effect not observed with
RyR1. In addition, purification of RyR2 also eliminated CaCaM-
dependent inhibition of [3H]ryanodine binding. This effect ap-
pears to be due to a conformational change in the purified
receptor rather than to the removal of a necessary cofactor
since single-channel measurements using purified RyR2 show
that upon application of a transmembrane potential, CaCaM
inhibition of the channel is restored. However, the KHi for
inhibition of channel open probability was considerably higher
than the KD for [
35S]CaM binding. Whether CaM binding af-
finity is voltage-dependent or whether restoration of function
correlates with unmasking of a second CaM binding site in
RyR2 is not known because CaM binding to single channels
cannot be measured. To resolve these issues, RyR2 mutants
lacking putative CaM binding sites need to be constructed and
examined.
Our data suggest that CaM is a major regulator of Ca21
release from intracellular stores during excitation-contraction
coupling. Under conditions of oxidative stress, such as exercise-
induced fatigue or ischemia in which levels of GSSG are in-
creased relative to GSH, the affinity for both apo- and CaCaM
is decreased. In skeletal muscle, the oxidizing effects can result
both in an increase (oxidation of RyR1) and decrease (decrease
in apoCaM affinity) of basal Ca21 release. One possible effect
consistent with our data is that oxidation will result in a
pronounced increase in peak Ca21 release, resulting from RyR1
oxidation and diminished CaCaM binding affinity. In cardiac
muscle, in the presence of Mg21 and adenine nucleotide, a shift
from reducing to oxidizing conditions will attenuate the inhi-
bition of RyR2 by saturating CaM at low Ca21 while eliminat-
ing inhibition by CaM at high Ca21. In addition, the CaM
binding affinity is reduced in the presence of oxidizing condi-
tions, further sensitizing the channel to activation by cytosolic
Ca21. This could lead to an increase in the sensitivity of RyR2
to trigger Ca21 provided by the dihydropyridine receptor. Fur-
thermore, CaM is a key mediator of Ca21-dependent inactiva-
tion and facilitation of cardiac L-type Ca21 channels (30–33)
and is, therefore, a regulator of two of the most tightly regu-
lated steps in excitation-contraction coupling.
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